CLNN - Clene's Neurogenerative Candidate Shows Potential For Improved Long-Term Survival | Benzinga
Clene Inc. (NASDAQ: CLNN) released long-term follow-up data for patients treated with CNM-Au8 30mg for up to 133 weeks in the HEALEY ALS Platform Trial.
These post hoc results showed significantly improved survival with a 49% decreased risk of death for the covariate risk-adjusted analyses as compared to the largest U.S. clinical database of previous amyotrophic lateral sclerosis (ALS) trials (PRO-ACT).
ALS is characterized by progressive degeneration of nerve cells in the spinal cord and brain.
In a pooled ...